Report cover image

Global Therapeutic Radioligands Drug Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Jul 07, 2025
Length 114 Pages
SKU # APRC20340154

Description

Summary

According to APO Research, The global Therapeutic Radioligands Drug market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Therapeutic Radioligands Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Therapeutic Radioligands Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Therapeutic Radioligands Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global companies of Therapeutic Radioligands Drug include Novartis, Mundipharma, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med and Nordic Nanovector, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Therapeutic Radioligands Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Therapeutic Radioligands Drug.

The Therapeutic Radioligands Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Therapeutic Radioligands Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Therapeutic Radioligands Drug Segment by Company

Novartis
Mundipharma
Bayer
Y-mAbs Therapeutics
Telix Pharmaceuticals
RadioMedix
Philogen
Orano Med
Nordic Nanovector
Lantheus
Gilead Sciences
Fusion Pharmaceuticals
Curium Pharmaceuticals
Curasight
Clarity Pharmaceuticals
China Isotope & Radiation
Aurobindo Pharma
Actinium Pharmaceuticals
Therapeutic Radioligands Drug Segment by Type

Beta-emitting
Targeted Alpha Therapy
Therapeutic Radioligands Drug Segment by Application

Solid Tumor
Non Hodgkin Lymphoma
Therapeutic Radioligands Drug Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Radioligands Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Radioligands Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Radioligands Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Therapeutic Radioligands Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

114 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.3 Global Therapeutic Radioligands Drug Market Size Overview by Region 2020 VS 2024 VS 2031
1.4 Global Therapeutic Radioligands Drug Market Size by Region (2020-2031)
1.4.1 Global Therapeutic Radioligands Drug Market Size by Region (2020-2025)
1.4.2 Global Therapeutic Radioligands Drug Market Size by Region (2026-2031)
1.5 Key Regions Therapeutic Radioligands Drug Market Size (2020-2031)
1.5.1 North America Therapeutic Radioligands Drug Market Size Growth Rate (2020-2031)
1.5.2 Europe Therapeutic Radioligands Drug Market Size Growth Rate (2020-2031)
1.5.3 Asia-Pacific Therapeutic Radioligands Drug Market Size Growth Rate (2020-2031)
1.5.4 South America Therapeutic Radioligands Drug Market Size Growth Rate (2020-2031)
1.5.5 Middle East & Africa Therapeutic Radioligands Drug Market Size Growth Rate (2020-2031)
2 Therapeutic Radioligands Drug Market by Type
2.1 Type Introduction
2.1.1 Beta-emitting
2.1.2 Targeted Alpha Therapy
2.2 Global Therapeutic Radioligands Drug Market Size by Type
2.2.1 Global Therapeutic Radioligands Drug Market Size Overview by Type (2020-2031)
2.2.2 Global Therapeutic Radioligands Drug Historic Market Size Review by Type (2020-2025)
2.2.3 Global Therapeutic Radioligands Drug Market Size Forecasted by Type (2026-2031)
2.3 Global Therapeutic Radioligands Drug Market Size by Regions
2.3.1 North America Therapeutic Radioligands Drug Market Size Breakdown by Type (2020-2025)
2.3.2 Europe Therapeutic Radioligands Drug Market Size Breakdown by Type (2020-2025)
2.3.3 Asia-Pacific Therapeutic Radioligands Drug Market Size Breakdown by Type (2020-2025)
2.3.4 South America Therapeutic Radioligands Drug Market Size Breakdown by Type (2020-2025)
2.3.5 Middle East and Africa Therapeutic Radioligands Drug Market Size Breakdown by Type (2020-2025)
3 Therapeutic Radioligands Drug Market by Application
3.1 Type Introduction
3.1.1 Solid Tumor
3.1.2 Non Hodgkin Lymphoma
3.2 Global Therapeutic Radioligands Drug Market Size by Application
3.2.1 Global Therapeutic Radioligands Drug Market Size Overview by Application (2020-2031)
3.2.2 Global Therapeutic Radioligands Drug Historic Market Size Review by Application (2020-2025)
3.2.3 Global Therapeutic Radioligands Drug Market Size Forecasted by Application (2026-2031)
3.3 Global Therapeutic Radioligands Drug Market Size by Regions
3.3.1 North America Therapeutic Radioligands Drug Market Size Breakdown by Application (2020-2025)
3.3.2 Europe Therapeutic Radioligands Drug Market Size Breakdown by Application (2020-2025)
3.3.3 Asia-Pacific Therapeutic Radioligands Drug Market Size Breakdown by Application (2020-2025)
3.3.4 South America Therapeutic Radioligands Drug Market Size Breakdown by Application (2020-2025)
3.3.5 Middle East and Africa Therapeutic Radioligands Drug Market Size Breakdown by Application (2020-2025)
4 Global Market Dynamics
4.1 Therapeutic Radioligands Drug Industry Trends
4.2 Therapeutic Radioligands Drug Industry Drivers
4.3 Therapeutic Radioligands Drug Industry Opportunities and Challenges
4.4 Therapeutic Radioligands Drug Industry Restraints
5 Competitive Insights by Company
5.1 Global Top Players by Therapeutic Radioligands Drug Revenue (2020-2025)
5.2 Global Therapeutic Radioligands Drug Industry Company Ranking, 2023 VS 2024 VS 2025
5.3 Global Therapeutic Radioligands Drug Key Company Headquarters & Area Served
5.4 Global Therapeutic Radioligands Drug Company, Product Type & Application
5.5 Global Therapeutic Radioligands Drug Company Commercialization Time
5.6 Market Competitive Analysis
5.6.1 Global Therapeutic Radioligands Drug Market CR5 and HHI
5.6.2 Global Top 5 and 10 Therapeutic Radioligands Drug Players Market Share by Revenue in 2024
5.6.3 2024 Therapeutic Radioligands Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
6.1 Novartis
6.1.1 Novartis Comapny Information
6.1.2 Novartis Business Overview
6.1.3 Novartis Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.1.4 Novartis Therapeutic Radioligands Drug Product Portfolio
6.1.5 Novartis Recent Developments
6.2 Mundipharma
6.2.1 Mundipharma Comapny Information
6.2.2 Mundipharma Business Overview
6.2.3 Mundipharma Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.2.4 Mundipharma Therapeutic Radioligands Drug Product Portfolio
6.2.5 Mundipharma Recent Developments
6.3 Bayer
6.3.1 Bayer Comapny Information
6.3.2 Bayer Business Overview
6.3.3 Bayer Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.3.4 Bayer Therapeutic Radioligands Drug Product Portfolio
6.3.5 Bayer Recent Developments
6.4 Y-mAbs Therapeutics
6.4.1 Y-mAbs Therapeutics Comapny Information
6.4.2 Y-mAbs Therapeutics Business Overview
6.4.3 Y-mAbs Therapeutics Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.4.4 Y-mAbs Therapeutics Therapeutic Radioligands Drug Product Portfolio
6.4.5 Y-mAbs Therapeutics Recent Developments
6.5 Telix Pharmaceuticals
6.5.1 Telix Pharmaceuticals Comapny Information
6.5.2 Telix Pharmaceuticals Business Overview
6.5.3 Telix Pharmaceuticals Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.5.4 Telix Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
6.5.5 Telix Pharmaceuticals Recent Developments
6.6 RadioMedix
6.6.1 RadioMedix Comapny Information
6.6.2 RadioMedix Business Overview
6.6.3 RadioMedix Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.6.4 RadioMedix Therapeutic Radioligands Drug Product Portfolio
6.6.5 RadioMedix Recent Developments
6.7 Philogen
6.7.1 Philogen Comapny Information
6.7.2 Philogen Business Overview
6.7.3 Philogen Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.7.4 Philogen Therapeutic Radioligands Drug Product Portfolio
6.7.5 Philogen Recent Developments
6.8 Orano Med
6.8.1 Orano Med Comapny Information
6.8.2 Orano Med Business Overview
6.8.3 Orano Med Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.8.4 Orano Med Therapeutic Radioligands Drug Product Portfolio
6.8.5 Orano Med Recent Developments
6.9 Nordic Nanovector
6.9.1 Nordic Nanovector Comapny Information
6.9.2 Nordic Nanovector Business Overview
6.9.3 Nordic Nanovector Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.9.4 Nordic Nanovector Therapeutic Radioligands Drug Product Portfolio
6.9.5 Nordic Nanovector Recent Developments
6.10 Lantheus
6.10.1 Lantheus Comapny Information
6.10.2 Lantheus Business Overview
6.10.3 Lantheus Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.10.4 Lantheus Therapeutic Radioligands Drug Product Portfolio
6.10.5 Lantheus Recent Developments
6.11 Gilead Sciences
6.11.1 Gilead Sciences Comapny Information
6.11.2 Gilead Sciences Business Overview
6.11.3 Gilead Sciences Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.11.4 Gilead Sciences Therapeutic Radioligands Drug Product Portfolio
6.11.5 Gilead Sciences Recent Developments
6.12 Fusion Pharmaceuticals
6.12.1 Fusion Pharmaceuticals Comapny Information
6.12.2 Fusion Pharmaceuticals Business Overview
6.12.3 Fusion Pharmaceuticals Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.12.4 Fusion Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
6.12.5 Fusion Pharmaceuticals Recent Developments
6.13 Curium Pharmaceuticals
6.13.1 Curium Pharmaceuticals Comapny Information
6.13.2 Curium Pharmaceuticals Business Overview
6.13.3 Curium Pharmaceuticals Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.13.4 Curium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
6.13.5 Curium Pharmaceuticals Recent Developments
6.14 Curasight
6.14.1 Curasight Comapny Information
6.14.2 Curasight Business Overview
6.14.3 Curasight Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.14.4 Curasight Therapeutic Radioligands Drug Product Portfolio
6.14.5 Curasight Recent Developments
6.15 Clarity Pharmaceuticals
6.15.1 Clarity Pharmaceuticals Comapny Information
6.15.2 Clarity Pharmaceuticals Business Overview
6.15.3 Clarity Pharmaceuticals Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.15.4 Clarity Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
6.15.5 Clarity Pharmaceuticals Recent Developments
6.16 China Isotope & Radiation
6.16.1 China Isotope & Radiation Comapny Information
6.16.2 China Isotope & Radiation Business Overview
6.16.3 China Isotope & Radiation Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.16.4 China Isotope & Radiation Therapeutic Radioligands Drug Product Portfolio
6.16.5 China Isotope & Radiation Recent Developments
6.17 Aurobindo Pharma
6.17.1 Aurobindo Pharma Comapny Information
6.17.2 Aurobindo Pharma Business Overview
6.17.3 Aurobindo Pharma Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.17.4 Aurobindo Pharma Therapeutic Radioligands Drug Product Portfolio
6.17.5 Aurobindo Pharma Recent Developments
6.18 Actinium Pharmaceuticals
6.18.1 Actinium Pharmaceuticals Comapny Information
6.18.2 Actinium Pharmaceuticals Business Overview
6.18.3 Actinium Pharmaceuticals Therapeutic Radioligands Drug Revenue, Global Share and Gross Margin (2020-2025)
6.18.4 Actinium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
6.18.5 Actinium Pharmaceuticals Recent Developments
7 North America
7.1 North America Therapeutic Radioligands Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2 North America Therapeutic Radioligands Drug Market Size by Country (2020-2025)
7.3 North America Therapeutic Radioligands Drug Market Size Forecast by Country (2026-2031)
8 Europe
8.1 Europe Therapeutic Radioligands Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2 Europe Therapeutic Radioligands Drug Market Size by Country (2020-2025)
8.3 Europe Therapeutic Radioligands Drug Market Size Forecast by Country (2026-2031)
9 Asia-Pacific
9.1 Asia-Pacific Therapeutic Radioligands Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2 Asia-Pacific Therapeutic Radioligands Drug Market Size by Country (2020-2025)
9.3 Asia-Pacific Therapeutic Radioligands Drug Market Size Forecast by Country (2026-2031)
10 South America
10.1 South America Therapeutic Radioligands Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2 South America Therapeutic Radioligands Drug Market Size by Country (2020-2025)
10.3 South America Therapeutic Radioligands Drug Market Size Forecast by Country (2026-2031)
11 Middle East & Africa
11.1 Middle East & Africa Therapeutic Radioligands Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2 Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2020-2025)
11.3 Middle East & Africa Therapeutic Radioligands Drug Market Size Forecast by Country (2026-2031)
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.